



1AP7 Rec'd PCT/PTO 20 MAR 2006

PCT
#A

Attorney Docket No. 270.PFUS
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dahl et al.

Serial No.: 10/540,794

Group No.: Unassigned

Filed: January 13, 2004

Examiner: Unassigned

For: COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

Commissioner for Patents
Mail Stop Amendments
P.O. Box 1450
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN
THREE MONTHS OF FILING OR BEFORE MAILING OF
FIRST OFFICE ACTION (37 CFR 1.97 (b))**

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(check and complete appropriate item below);

37 CFR 1.8 (a)
☒ with sufficient postage as
first class mail

or

37 CFR 1.10
☐ as "Express Mail Post
Office to Addressee" Mailing
Label
No. _____

Date:

March 17, 2006

Robin Torres

(Type or print name of person mailing paper)


Robin Torres
(Signature of person mailing paper)

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Reg. No. 27,043

Tel. No.: (650) 522-5535



SIGNATURE OF ATTORNEY
Max D. Hensley

Type or print name of attorney
Gilead Sciences, Inc.
333 Lakeside Drive

P.O. Address
Foster City, CA 94404

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dahl et al.

Serial No.: 10/540,794

Group No.: Unassigned

Filed: January 13, 2004

Examiner: Unassigned

For: COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

Commissioner for Patents
Mail Stop Amendments
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☒ Copies of Listed Information Items Accompanying This Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Robin Torres

(Type or print name of person mailing paper)

Date: March 17, 2006




(Signature of person mailing paper)

Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 27,043

Tel. No.: (650) 522-5535



SIGNATURE OF ATTORNEY

Max D. Hensley

Type or print name of attorney

Gilead Sciences, Inc.

333 Lakeside Drive

P.O. Address

Foster City, CA 94404

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**
**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(37 CFR 1.98(b))

ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794

APPLICANT: Dahl et al

FILING DATE: 1/13/2004

GROUP ART UNIT:

EXAMINER NAME:

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US - 4,724,233	02-09-1988	De Clercq et al	
		US - 4,808,716	02-28-1989	Holy et al.	
		US - 4,816,570	03-28-1989	Farquhar, David	
		US - 4,968,788	11-06-1990	Farquhar, David	
		US - 5,047,407	09-10-1991	Belleau et al.	
		US - 5,151,426	10-29-1992	Belleau et al.	
		US - 5,179,104	01-12-1993	Chu et al.	
		US - 5,204,466	04-20-1993	Liotta et al.	
		US - 5,210,085	05-11-1993	Liotta et al.	
		US - 5,466,806	11-14-1995	Belleau et al.	
		US - 5,486,520	01-23-1996	Belleau et al.	
		US - 5,538,975	07-23-1996	Dionne, Gervais	
		US - 5,587,480	12-24-1996	Belleau et al	
		US - 5,618,820	04-08-1997	Dionne, Gervais	
		US - 5,627,186	05-06-0197	Cameron et al.	
		US - 5,663,159	09-02-1997	Starrett, Jr. et al.	
		US - 5,696,254	12-09-1997	Mansour et al.	
		US - 5,733,788	03-31-1998	Bischofberger, Norbert	
		US - 5,744,596	04-28-1998	Mansour et al.	
		US - 5,756,706	05-26-1998	Mansour et al.	
		US - 5,763,606	06-09-1998	Mansour et al.	
		US - 5,792,756	08-11-1998	STARRETT JR. et al	
		US - 5,814,639	09-29-1998	Liotta et al.	
		US - 5,859,021	01-12-1999	Cameron et al.	
		US - 5,905,082	05-18-1999	Roberts et al.	
		US - 5,914,331	06-22-1999	Liotta et al.	
		US - 5,922,695	07-13-1999	Arimilli et al.	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(37 CFR 1.98(b))</small>	ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794 <hr/> APPLICANT: Dahl et al <hr/> FILING DATE: 1/13/2004 GROUP ART UNIT: <hr/> EXAMINER NAME: <hr/>
Sheet 2 of 4	

Examiner initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US - 5,935,946	08-10-1999	Munger, Jr. et al.	
		US - 5,977,089	11-02-1999	Arimilli et al	
		US - 6,043,230	03-28-00	Arimilli et al.	
		US - 6,057,305	05-02-00	Holy et al.	
		US - 6,069,249	05-30-00	Arimilli et al.	
		US - 6,113,920	09-05-00	Maye et al.	
		US - 6,114,343	09-05-00	Liotta et al.	
		US - 6,312,662	11-06-01	ERION et al	

FOREIGN PATENT DOCUMENTS						
Examiner initial	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T
		WO 00/25797	05-11-00	TRIANGLE PHARMACEUTICALS, INC.		
		WO 02/068058	09-06-02	TRIANGLE PHARMACEUTICALS, INC.		
		WO 02/070518 A1	09-12-02	TRIANGLE PHARMACEUTICALS, INC		
		WO 02/08241	01-31-02	GILEAD SCIENCES, INC		
		WO 91/19721	12-26-1991	Glazier, Arnold		
		WO 92/14743	09-03-1992	EMORY UNIVERSITY		

NON PATENT LITERATURE DOCUMENTS			
Examiner initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volumn-issue number(s), publisher, city and/or country where published.	T
		BLACKBURN ET AL., "DNA and RNA structure", pp.15-81, NUCLEIC ACIDS IN CHEMISTRY AND BIOLOGY, 1996	
		BUNDGAARD ET AL, "Design and Application of Prodrugs", pp.113-191, TEXTBOOK OF DRUG DESIGN AND DEVELOPMENT, 1991	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(37 CFR 1.98(b))</small>	ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794	
	APPLICANT: Dahl et al	
	FILING DATE: 1/13/2004	GROUP ART UNIT:
	EXAMINER NAME:	
Sheet 3 of 4		

Examiner initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volumn-issue number(s), publisher, city and/or country where published.	T
		BENZARIA ET AL, "Synthesis, in Vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2 thioethyl) Ester Derivatives of 9-[2-(Phosphonometyoxy)ethyl]adenine (PMEA) as Potential PMEA Prodrugs with Improved Oral Bioavailability ", 39:4958-4965, J MED CHEM, 1996	
		DE LOMBAERT ET, "N-Phosphonomethyl Dipeptides and heir Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitor", 37:498-511, J MED CHEM, 1994	
		DE CLERCQ, ERIK, "New Anti-HIV Agents and Targets", 22(6):531-565, MEDICINAL RESEARCH REVIEWS, 2002	
		FARQUHAR ET AL, "Biologically Reversible Phosphate-Protective Groups", 72:324-325, J PHARM SCI, 1983	
		FASMAN ET AL, "", pp 385-394, PRACTICAL HANDBOOK OF BIOCHEM AND MOLEC BIOL, 1989	
		FELL ET AL, "", 20:657-659, J PHARM PHARMACOL, 1968	
		FREEMAN ET AL., "3 Prodrug Design for Phosphate and Phosphonates", 34:112-147, PROGRESS IN MEDICINAL CHEMISTRY, 1997	
		FUNG, HORATIO B., "Tenofovir Disoproxil Fumarate: A Nucleotide Reverse Transcriptase Inhibitor for the Treatment of HIV Infection", 24(10):1515-1548, CLINICAL THERAPEUTICS, 2002	
		GILEAD SCIENCES, INC., "Data Comparing Viread (R) and Emtriva (R) to Combivir (R) as Part of Combination HIV Therapy Published in New England Journal of Medicine", pg. 1-5, Press Release, 2006	
		GILEAD SCIENCES, INC., "U.S. FDA Approves Gilead Sciences' Emtriva A one-capsule, Once-Daily Medication For The Treatment of HIV", pg.3-7, Press Release, 2003	
		HOSTETLER ET AL, "Greatly Enhanced Inhibition of Human Immunodeficiency Virus Type 1 Replication in CEM and HT4-6C Cells by 3'-Deoxythymidine Diphosphate Dimyristoylglycerol, a Lipid Prodrug of 3' -Deoxythymidine", 36(9):2025-2029, ANTIMICRO AG & CHEMO, 1992	
		HOSTETLER ET AL., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides", 265(11):6112-6117, J BIOL CHEM, 1990	
		JONES ET AL., "Minireview: nucleotide prodrugs", 27:1-17, ANTIVIRAL RES, 1995	
		KHAMNEI ET AL, "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs", 39:4109-4115, J MED CHEM, 1996	
		KUCERA ET AL, "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation", 6:491-501, AIDS RES & HUM RETRO, 1990	
		LOVEDAY, C., "Nucleoside reverse transcriptase inhibitor resistance", 26:S10-S24, JAIDS, 2001	
		LIEBERMAN ET AL, "", 1:177-178, PHARMACEUTICAL DOSAGE FORMS, 1989	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(37 CFR 1.98(b))</small>	ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794	
	APPLICANT: Dahl et al	
	FILING DATE: 1/13/2004	GROUP ART UNIT:
	EXAMINER NAME:	
Sheet 4 of 4		

Examiner initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		MULATO ET AL, "Anti-HIV Activity of Adefovir (PMEA) and PMPA In Combination With Antiretroviral Compounds: In Vitro Analyses", 36(2):91-97, ANTIVIRAL RES, 1997	
		MURRY ET AL, "Reversion of the M184V Mutation in Simian Immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine", 77(2):1120-1130, J VIROL, 2003	
		PALLELLA ET AL., "", 338:853-860, J MED CHEM, 1998	
		PUECH ET AL., "Intracellular delivery of nucleoside monophosphates through a reuctase-mediated activation process", 22:155-174, ANTIVIRAL RES, 1993	
		PIANTADOSI ET AL., "Synthesis and Evaluation of Novel Ether Lipd Nucleoside Conjugates for Anti-HIV-1 Activity", 34:1408-1414, J MED CHEM, 1991	
		RICHMAN, DOUGLAS, "The use of chemotherapy to supress replication of the human immunodeficiency virus(HIV) has transformed the face of AIDS in the developed world. Pronounced reductions in illness and death have been achieved and healthcare utilization has diminished. HIV", 410:995-1001, NATURE, 2001	
		RICHMAN, DOUGLAS D., "Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor", 6:83-88, ANTIVIRAL THERAPY, 2001	
		RISTIG, MARIA B., "Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/ Hepatitis B Virus - Coinfected Individuals for Whom Interferon- and Lamivudine Therapy Have Failed.", 186:1844-1847, JOURN OF INFECT DISEASE, 2002	
		SIDDIQUI ET AL., "Design and Synthesis of Lipophilic Phosphoramidate D4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for In Vitro Activity and QSAR", 42(20):4122-4128, J MED CHEM, 1999	
		YENI ET AL, "Antiretroviral Treatment for Adult HIV Infection in 2002", 288(2):222-235, JAMA, 2002	
		YUAN ET AL, "Degradation Kinetics of Oxycarbonyloxymethyl Prodrugs of Phosphonates in Solution", 18(2):234-237, PHARM RES, 2001	
		WWW.PROJECTINFORM.ORG, "Anti-HIV Drug Updates- Three Drugs on the Near Horizon", 35:4-7, PI Perspective, 2003	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	